{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-110241","form_type":"8-K","ticker":"CLYD","cik":"0002094256","company_name":"BEACON TOPCO, INC.","filed_at":"2026-09-24T13:19:17+00:00","discovered_at":"2026-09-24T13:20:00.517881+00:00","generated_at":"2026-09-24T13:20:11.217091+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Balomenib Phase 1b shows durable HbA1c improvement; Merger closing extended to Oct 31","bullets":["Merger closing date for Clywedog acquisition amended to Oct 31, 2026 (or earlier mutual agreement); End Date also Oct 31, 2026.","Phase 1b: placebo-adjusted HbA1c -0.77% at Week 12 (p<0.01) and -0.70% at Week 16 (p<0.05) after 3-week dosing.","OGTT: placebo-adjusted reductions in total glucose AUC 203 mmol·min/L (p=0.019), peak glucose 2.03 mmol/L (p=0.013), 2-hr glucose 2.46 mmol/L (p=0.010).","FPG reduced by 1.29 mmol/L (23 mg/dL) at Week 12 (p<0.05); no drug-related serious/severe AEs or discontinuations.","Phase 2a with 12-week treatment course expected to initiate in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-110241","json":"https://secwatch.observer/filing/0001104659-26-110241.json","markdown":"https://secwatch.observer/filing/0001104659-26-110241.md","text":"https://secwatch.observer/filing/0001104659-26-110241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2094256/000110465926110241/0001104659-26-110241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2094256/000110465926110241/tm2625953d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T13:20:11.217091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}